Semax Research for Stroke Recovery
An evidence-based overview of research examining Semax in the context of stroke recovery. This page synthesizes findings from peer-reviewed literature.
Research Summary
Semax is approved in Russia for ischemic stroke treatment and rehabilitation. Clinical trials have demonstrated neuroprotective effects in acute stroke and improved functional recovery during rehabilitation phases. The peptide reduces infarct volume and suppresses inflammatory cascades that cause secondary brain damage.
A controlled clinical trial of 110 post-stroke patients showed that Semax combined with rehabilitation significantly increased plasma BDNF levels, accelerated functional recovery, and improved Barthel index scores compared to rehabilitation alone. Early intervention showed the greatest benefits.
Genome-wide transcriptomic studies have characterized the molecular mechanisms, showing suppression of pro-inflammatory cytokines (IL-1, IL-6, TNF-alpha) and activation of neurotransmission genes, providing mechanistic support for the clinical observations.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Stroke Recovery
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Semax may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.